Sangamo Therapeutics, Inc.SGMONASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts are neutral — opinion is divided on direction.

Consensus Rating

Hold

13 analysts·Moderate coverage

46%

Rating Distribution

Strong Buy

00%

Buy

646%

Hold

646%

Sell

18%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 1254% higher.

Bear Case

$2.00

+273%

Consensus

$7.25

+1254%

Bull Case

$19.00

+3448%

Price Range13 analysts

Low

Consensus

High

$2.00

$19.00

Current Target

Current Price

$0.54

Upside to Target

$6.71

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.31(2 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+164.24%

EPS—

FY2028

Rev+84.27%

EPS—

FY2029

Rev+49.02%

EPS+90.83%

Earnings Surprises

Beat rate:25%(3/12 quarters)

Avg surprise:-1.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 31, 2024Jefferies

Sangamo price target lowered to $3 from $7 at Jefferies

Target:$3.00

+194.1%from $1.02

Dec 31, 2024Wells Fargo

Sangamo price target lowered to $2 from $3 at Wells Fargo

Target:$2.00

+96.1%from $1.02

Jun 13, 2022Wedbush

Sangamo assumed with a Neutral at Wedbush

Target:$5.00

+33.0%from $3.76

Apr 5, 2022Truist Financial

Sangamo BioSciences (SGMO) Stock: Why The Price Increased

Target:$19.00

+208.9%from $6.15

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance